Medgenisis Announces Issue of Options and Restricted Shares to Directors and Officers  
1/9/2012 6:39:08 AM

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, pursuant to approvals given at a Board meeting held on 9 December 2011, on 3 January 2012 it (i) granted options to subscribe for 15,000 common shares (“Options”) and (ii) made a restricted share award of 7,000 common shares of par value US$0.0001 each (“Common Shares”) in the Company (“Restricted Shares”) to each of Isaac Blech, Gary Brukardt, Alastair Clemow, Joel Kanter, and Stephen McMurray, all non-executive directors of the Company, as part of their remuneration for the year.